INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

(2018) S Verstovsek et al.   ANNALS OF ONCOLOGY

Comprehensive Characterization of Cancer Driver Genes and Mutations

(2018) Matthew H. Bailey et al.   CELL

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma

(2014) M. Capelletti et al.   CLINICAL CANCER RESEARCH

Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations

(2014) Howard R. Mellor   LIVER INTERNATIONAL

Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer

(2014) J. M. Drake et al.   MOLECULAR AND CELLULAR BIOLOGY

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations

(2013) Han Kiat Ho et al.   DRUG DISCOVERY TODAY

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

(2012) P. R. Gavine et al.   CANCER RESEARCH

Oncogenic FGFR3 gene fusions in bladder cancer

(2012) Sarah V. Williams et al.   HUMAN MOLECULAR GENETICS

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets

(2012) Simon Wöhrle et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease

(2011) N. Itoh et al.   JOURNAL OF BIOCHEMISTRY

Targeting mutant fibroblast growth factor receptors in cancer

(2011) Heidi Greulich et al.   TRENDS IN MOLECULAR MEDICINE

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

(2010) F R Lamont et al.   BRITISH JOURNAL OF CANCER

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

8p11 myeloproliferative syndrome: a review

(2010) Courtney C. Jackson et al.   HUMAN PATHOLOGY

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo

(2009) O. E. Pardo et al.   CANCER RESEARCH

De-regulated FGF receptors as therapeutic targets in cancer

(2009) Victoria Knights et al.   PHARMACOLOGY & THERAPEUTICS

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA